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Abstract: Background: The recombinant IL-1 receptor antagonist anakinra—currently approved
for the treatment of autoinflammatory diseases—blocks IL-1β-mediated inflammatory signaling.
As inflammation is a major driver of cancer, we hypothesized that anakinra might be able to mitigate
glioblastoma (GBM) aggressiveness. Methods: Primary GBM or T98G cells were incubated alone or
with peripheral blood mononuclear cells (PBMCs) and were subsequently treated with IL-1β and/or
anakinra. T cells were obtained by magnetic bead isolation. Protein and mRNA expression were
quantified by SDS-PAGE, qRT-PCR, and ELISA, respectively. Cell proliferation and apoptosis were
analyzed via flow cytometry. Chemotaxis was studied via time-lapse microscopy. Results: Upon IL-1β
stimulation, anakinra attenuated proinflammatory gene expression in both GBM cells and PBMCs,
and mitigated tumor migration and proliferation. In a more lifelike model replacing IL-1β stimulation
by GBM–PBMC co-culture, sole presence of PBMCs proved sufficient to induce a proinflammatory
phenotype in GBM cells with enhanced proliferation and migration rates and attenuated apoptosis.
Anakinra antagonized these pro-tumorigenic effects and, moreover, reduced inflammatory signaling
in T cells without compromising anti-tumor effector molecules. Conclusion: By dampening the
inflammatory crosstalk between GBM and immune cells, anakinra mitigated GBM aggressiveness.
Hence, counteracting IL-1β-mediated inflammation might be a promising strategy to pursue.
Keywords: glioblastoma; inflammation; IL-1β; anakinra
1. Introduction
Inflammation has emerged as a major promoter of all stages of tumorigenesis [1–3]. Intricate
networks of tumor-associated inflammation are driven by a perpetual crosstalk between cancer and
tumor-infiltrating immune cells, which has mutually reinforcing effects and boosts the production of
cytokine mediators by both immune and tumor cells [4–6]. The resulting inflammatory milieu not
only promotes tumor progression, but also blocks anti-tumor immunity by impairing functions of
the adaptive immune system [7,8]. Interleukin (IL)-1β has emerged as the master cytokine activating
inflammatory signaling pathways in both cancer and immune cells [9–11]. In particular, in the tumor
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microenvironment (TME) of glioblastomas (GBM), IL-1β is extensively abundant [11–13]. Thus, blocking
IL-1β might ameliorate the vicious cycle of self-aggravating inflammation and might reduce GBM
aggressiveness [14,15]. In this scenario, the recombinant IL-1 receptor antagonist anakinra, routinely
used in the treatment of autoimmune diseases, might hold potential as a promising new therapeutic
approach [15,16].
In the current study, we addressed this issue in an in vitro model of the tumor microenvironment
consisting of primary human GBM cells and human immune cells. We were able to provide
evidence that anakinra exerts its effects in both GBM and immune cells: It puts the brake on
tumor-promoting inflammatory signaling pathways in GBM and simultaneously promotes a shift
towards an anti-inflammatory T cell phenotype without impairing anti-tumor immunity. As a result,
anakinra diminishes GBM proliferation, migration, and invasion. Our findings indicate that
administration of anakinra might be an interesting and novel therapeutic approach to reduce
glioblastoma aggressiveness.
2. Results
2.1. Anakinra Dampened IL-1β-Induced Inflammatory Gene Expression in GBM and PBMC
We first assessed the impact of the “master cytokine” IL-1β on proinflammatory gene expression
in primary GBM cells and peripheral blood mononuclear cells (PBMC) [17]. As shown in Figure 1,
IL-1β stimulation resulted in a marked increase of the proinflammatory genes IL-1β, COX-2, CCL2,
and IL-8 in both GBM cells (Figure 1A: IL-1β: +13.73-fold ± 3.62, COX-2: +17.2-fold ± 5.65, CCL2:
+2.90-fold ± 1.65, IL-8: +11.1-fold ± 3.64, n = 6, p < 0.041) and PBMCs (Figure 1B: IL-1β: +15.1-fold ±
1.31, COX-2: +2.57-fold ± 0.27, CCL2: +8.77-fold ± 1.63, IL-8: +8.22-fold ± 1.22, n = 5, p < 0.008). After
an IL-1β stimulation period of 3h, administration of anakinra (1 µg/mL, dose-finding is depicted in
Figure S1A,B) strongly diminished expression of these cytokines in both cell populations (Figure 1A,B:
GBM: IL-1β: −80.6% ± 25.2%, COX-2: −92.3% ± 30.9%, CCL2: −70.3% ± 40.2%, IL-8: −85.7 ± 29.9%,
n = 6; p < 0.041; PBMC: IL-1β: −93.3 ± 8.1 %, COX-2: −69.0% ± 7.9%, CCL2: −88.8% ± 15.9%, IL-8:
−86.0% ± 11.8%, n = 5, p < 0.008).
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Figure 1. Anakinra dampened IL-1β-induced inflammatory gene expression in primary glioblastoma 
(GBM) cells and peripheral blood mononuclear cells (PBMCs). GBM cells and PBMCs were separately 
stimulated with IL-1β. Anakinra (Ana) was administered after 3h of incubation. mRNA expression 
levels of proinflammatory IL-1β, COX-2, CCL2, and IL-8 were quantified by qRT-PCR. (A) mRNA 
expression of proinflammatory cytokines in GBM (n = 6, p < 0.041). (B) mRNA expression of 
proinflammatory cytokines in PBMCs (n = 5, p < 0.008). *p < 0.05, **p < 0.01, ***p < 0.001. 
Primary GBM, T98G, and U87 cells responded to anakinra treatment after IL-1β stimulation in a 
comparable manner (T98G/U87: Figure S1B/C). As the features of T98G cells provide a more life-like 
model of human GBM in contrast to U87 cells regarding their MGMT methylation status [18], primary 
GBM and T98G cells were mainly used for subsequent experiments. 
Figure 1. Anakinra dampened IL-1β-induced inflammatory gene expression in primary glioblastoma
(GBM) cells and peripheral blood mononuclear cells (PBMCs). GBM cells and PBMCs were separately
stimulated with IL-1β. Anakinra (Ana) was administered after 3h of incubation. mRNA expression
levels of proinflammatory IL-1β, COX-2, L2, a d IL-8 were quantified by qRT-PCR. (A) mRNA
expr ssion f proinflammatory cytokines in 6, p < .041). (B) mRNA xpression of
proinflammatory cytokines in PBMCs (n = 5, 0.008). * p < 0.05, ** p < 0.01, *** p < 0.001.
Primary GBM, T98G, and U87 cells respo anakinra treatment after IL-1β stimulation in a
comparable manner (T98G/U87: Figure S1B, ). s t e features of T98G cells provide a more life-like
model of human GBM in contrast to U87 cells regarding their MGMT methylation status [18], primary
GBM and T98G cells were mainly used for subsequent experiments.
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2.2. Anakinra Inhibited IL-1β-Induced Tumor Proliferation and Migration
We next assessed the impact of IL-1β administration on GBM cell proliferation, migration, and
apoptosis by intracellular flow cytometry and migration assay, respectively. Upon stimulation of
GBM cells with IL-1β, we detected an increased proliferation rate as determined by Ki-67 protein
levels [19] (Figure 2A: +19.8% ± 17.4%, n = 5, p = n.s.). This effect was significantly inhibited by
administration of anakinra (Figure 2A: −21.0% ± 5.1%, n = 5, p = 0.027). Furthermore, we conducted
time-lapse microscopy to assess the impact of IL-1β on GBM cell migration. As depicted in Figure 2B,
an enhancement of directed migration towards a chemotactic stimulus was found (+1.49-fold % ± 0.98,
n = 4, p = n.s.), whereas anakinra treatment blocked this pro-invasive effect of IL-1β (Figure 2B:
−1.13-fold ± 0.37, n = 4, p = 0.048). Similar results were obtained using primary GBM cells (Figure S2).
These findings were also corroborated in transwell invasion (Figure 2C) and 2D migration assays
(Figure 2D), revealing a less invasive GBM phenotype after administration of anakinra. Tumor cell
invasion was significantly enhanced by IL-1β (Figure 2C: +37.8% ± 2.9%, n = 3, p = 0.047), and anakinra
markedly attenuated the invasive capacity of tumor cells (Figure 2C: −23.4% ± 2.7%, n = 3, p = 0.048).
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experiments is shown (left panel, n = 4). Analysis of forward migration index (FMI, coordinate of a 
cell in the indicated direction (x-axis) divided by the accumulated distance of its paths, representing 
efficiency of forward migration) (right panel, n = 4, p = 0.048). (C) Analysis of tumor cell invasion by 
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Figure 2. GBM proliferation, migration, and invasion, promoted by IL-1β stimulation, was mitigated
after treatment with anakinra (Ana). T98G cells were stimulated with IL-1β in the presence or
absence of kinra. (A) Quantification of Ki-67-positive T98G cells by flow cytometry (n = 5,
p = 0.027). One representative histogram is shown. (B) Analysis of chemotaxis time-lapse microscopy
by single-cell tracking. IL-1β-stimulated T98G cells were incubated with FCS as a chemotactic stimulus
(right reservoir). At least 40 cells were tracked. One representative example of four independent
experiments is shown (left panel, n = 4). Analysis of forward migration index (FMI, coordinate of a
cell in the indicated di ection (x-axis) divided by the accumulated distance of its paths, representing
efficiency of forward migration) (right panel, n = 4, p = 0.048). (C) Analysis of tumor cell invasion
by transwell invasion assay. Stimulated T98G cells were seeded in cell culture inserts and allowed
to migrate towards FCS as a chemotactic stimulus. Optical density of invasive T98G represents the
amount of transmigrated cells (n = 3, p < 0.05). (D) 2D migration assay of GBM cells, stimulated with
IL-1β in the presence or absence of anakinra at start and after 12h. Lines mark the initially cell-free area.
A typical example of six experiments is shown (n = 6). * p < 0.05.
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IL-1β is known to act as an inhibitor of tumor apoptosis via the induction of signal transducer and
activator of transcription 3 (STAT3) [11,20–22]. Concordantly, we found a trend towards IL-1β-induced
induction of STAT3 expression and reduced apoptosis rates in GBM cells. These effects were slightly
attenuated by anakinra, however, without reaching statistical significance (Figure S3).
Collectively, these results suggest that two main features of GBM cell aggressiveness, proliferation
and migration, are amplified by IL-1β-signaling, which can be prevented by anakinra administration
in vitro.
2.3. Anakinra Dampened Inflammatory Crosstalk between GBM and Immune Cells, Resulting in a Less Aggressive
GBM Phenotype
We next aimed to investigate the effects of anakinra in a model mimicking the tumor
microenvironment. To this end, we established a protocol of indirect co-cultivation of GBM cells
and PBMCs under moderate hypoxic conditions (5% O2). Surprisingly, indirect co-incubation of
GBM cells and PBMCs, without any additional stimuli, was sufficient to dramatically increase the
expression of proinflammatory genes and STAT3 in GBM cells (Figure 3A: IL-1β: +70.7% ± 32.4%,
COX-2: +79.9% ± 51.8%, CCL2: +5.81-fold ± 2.04, IL-8: +14.11-fold ± 4.66, n = 7, p < 0.040; Figure 3B:
STAT3: +26.9% ± 5.1%, n = 7, p = 0.006). Anakinra treatment was also able to abrogate induction of all
genes investigated (Figure 3A: IL-1β: −64.0% ± 19.1%, COX-2: −56.3% ± 21.4%, CCL2: −87.1% ± 46.0%,
IL-8: −91.7% ± 27.0%, n = 7, p < 0.040; Figure 3B: STAT3: −11.0 % ± 3.2%, n = 7, p = 0.015). We next
assessed proliferation, migration, and apoptosis rates of T98G cells from co-culture experiments.
As shown in Figure 3C and D, indirect contact with immune cells increased GBM proliferation rates
(Figure 3C: +52.0% ± 17.5%, n = 6, p = 0.048) and enhanced directed tumor cell migration towards a
chemotactic stimulus (Figure 3D: +3.36-fold ± 1.77, n = 4, p = n.s). Application of anakinra resulted
in significantly reduced expression levels of Ki-67 (Figure 3C: −25.2% ± 6.8%, n = 6, p = 0.019)
and, furthermore, was able to block the pro-migratory effects induced by GBM–PBMC co-culturing
(Figure 3D: −1.09-fold ± 0.17, n = 4, p = 0.008).
However, apoptosis of GBM cells was not affected by indirect co-culturing (data not shown), which
led us to assume that direct cell–cell contact might be needed for induction of these signaling pathways.
To this end, we directly co-cultured GBM cells with PBMCs. To deal with the difficulty of separating
tumor cells from immune cells after direct incubation, we proceeded in two steps: (1) We harvested the
supernatant of these direct co-cultures and (2) subsequently subjected it to GBM cell cultures. After an
incubation time of 24 hours, we determined antiapoptotic BCL-2 mRNA and protein (densitometric
analysis) expression, mRNA expression of proapoptotic BAX, and apoptosis rate. Incubation with
supernatant from untreated co-cultures increased mRNA and protein expression of BCL-2 in native
T98G cells (Figure 4A: mRNA: +76.9% ± 7.7%, n = 6, p = 0.031; protein: +20.3% ± 14.2%, n = 3) and
reduced the BAX/BCL-2 ratio, an established parameter determining the response to possible pro-
or anti-apoptotic stimuli [23,24] (Figure 4B: −47.6% ± 9.1%, n = 3, p = 0.015). Concordantly, T98G
apoptosis rate was reduced (Figure 4C: −63.7% ± 23.0%, n = 6, p = 0.048). When incubated with
anakinra-treated direct co-culture supernatant, T98G cells displayed significantly diminished mRNA
and protein levels of BCL-2 (Figure 4A: mRNA: −18.3% ± 7.5%, n = 6, p = 0.013; protein: −22.5% ± 3.5%,
n = 3). The BAX/BCL-2 ratio was induced significantly (Figure 4B: +36.5% ± 13.1%, n = 3, p = 0.049).
In line with these findings, the percentage of apoptotic GBM cells, as measured by flow cytometry, was
increased (Figure 4C: +43.6% ± 8.4%, n = 6, p = 0.002).
Taken together, these results provide evidence that the presence of PBMCs alone is sufficient to
induce a proinflammatory phenotype in GBM cells, which in turn enhances GBM cell proliferation
and migration and inhibits apoptosis. In contrast, treatment with anakinra attenuates inflammatory
gene expression, inhibits proliferation, attenuates migration, and induces apoptosis. Thus, anakinra
treatment induces a more benign GBM cell phenotype.
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Figure 3. Anakinra inhibited co-culture-induced expression of proinflammatory cytokines and signal
transducer and activator of tr nscription 3 (STAT3) in GBM and inhibits tumor p oliferation and migration.
T98G cells were indirectly incubated with PBMCs. (A) mRNA expression of proinflammatory cytokines
in T98G (n = 7, p < 0.040). (B) mRNA expression of transcription factor STAT3 in T98G (n = 7, p < 0.016).
(C) Quantification of Ki-67-positive T98G cells by flow cytometry (n = 6, p < 0.05). One representative
histogram is shown. (D) Analysis of chemotaxis ti e-lapse microscopy by single-cell tracking. T98G
cells from indirect co-cultures were incubated with FCS as a chemotactic stimulus (right reservoir).
At least 40 cells were tracked. One representative example of four independent experiments is shown
(left panel, n = 4). Analysis of forward migration index (FMI, coordinate of a cell in the indicated
direction (x-axis) divided by the accumulated distance of its paths, representing efficiency of forward
migration) (right panel, n = 4, p = 0.008). * p < 0.05, ** p < 0.01.
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2.4. Anakinra Reduced Inflammatory Signaling in Lymphocytes Co-Cultured With GBM Cells
Effective adaptive immunity is essential for long-term tumor control. On the other hand,
inadequate proinflammatory cytokine secretion by T cells can support tumor growth and progression [7].
We assumed that anakinra might also affect these aspects of tumor-associated inflammation. We thus
extracted T cells after indirect co-culture of PBMCs and GBM cells and analyzed expression levels of
inflammatory cytokines that were (a) secreted by T cells and (b) involved in oncogenic signaling [25–27].
After administration of anakinra, we detected a marked decrease of proinflammatory IFNγ, IL-17,
and IL-22 mRNA expression (Figure 5A: IFNγ: −85.0% ± 45.4%, IL-17: −88.1% ± 21.7%, IL-22:
−63.2% ± 22.0%, n = 13, p < 0.004) in these T cells as well as reduced protein levels in the respective
conditioned medium (Figure 5A: IFNγ: −13.04% ±3.3, IL-17: −51.8% ± 20.8%, IL-22: −37.1% ± 8.5%,
n = 10, p < 0.004). Notably, anakinra did not alter perforin (PRF1) or granzyme B (GZMB) levels in
cytotoxic T cells (Figure 5B, n = 9), suggesting that CD8+-T-cell-mediated antitumor immunity remains
unaffected after anakinra treatment. In addition, anakinra promoted gene expression and protein
secretion of the anti-inflammatory cytokine IL-10 (Figure 5C: mRNA: +64.5% ± 30.0%, n = 13, p = 0.038;
protein: +15.5% ± 5.1%, n = 10, p = 0.002).Cancers 2020 7 of 14 
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Figure 5. Anakinra reduced inflammatory signaling in lymphocytes co-cultured with T98G cells. T
cells were isolated from PBMC after indirect co-culture with or without (w/o) anakinra (Ana). Protein
levels in conditioned media from indirect co-cultures were assessed by enzyme-linked immunosorbent
assay (ELISA). (A) mRNA and protein levels of proinflammatory cytokines IFNγ, IL-17, and IL-22
(mRNA: n = 13; protein: n = 10, p < 0.004). (B) mRNA expression of cytotoxic T-cell effector molecules
PRF1 and GZMB (n = 9). (C) mRNA and protein level of anti-inflammatory cytokine IL-10 (mRNA:
n = 13, p = 0.038; protein: n = 10, p = 0.002). * p < 0.05, ** p < 0.01.
3. Discussion
Tumor-promoting inflammation is an important driver of GBM progression. Inflammatory
mediators are secreted by both tumor and immune cells in a mutually reinforcing manner [5,28]. In this
study, we uncovered a new strategy to ameliorate this inflammatory feed-forward loop. We showed
that the IL-1 antagonist anakinra puts the brake on inflammatory gene expression in both GBM and
immune cells, and thereby attenuates GBM cell aggressiveness.
Interleukin-1β (IL-1β) is the “master regulator” of innate immunity and one of the most potent
inflammatory cytokines. It is secreted by both immune and GBM cells [11,29], and treatment of GBM
cells with IL-1β has been shown to enhance migration, invasion, and proliferation [17,30]. This more
aggressive GBM phenotype has been attributed to increased levels of the tumor-promoting cytokine
IL-6 and induction of STAT3 [31,32]. However, the actual role of IL-1β within the inflammatory
networks of the tumor environment has not been investigated to date. We treated GBM cells and
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PBMCs with IL-1β and found dramatically increased expression levels of the proinflammatory and
tumor-promoting mediators COX2, IL-1β, CCL2, and IL-8 [33–38] in both GBM cells and PBMCs.
Moreover, functional assays revealed a significant induction of GBM cell proliferation and migration.
IL-1β is known to influence apoptosis of tumor cells via induction of STAT3 [11,20–22] Concordantly,
we found a tendency towards up-regulation of STAT3 and decreased apoptosis rates in GBM cells
after IL-1β treatment (Figure S3). These results let us to assume that IL-1β might contribute to an
inflammatory milieu that fosters GBM aggressiveness, and that blocking IL-1β-dependent pathways
might be a promising strategy. Indeed, application of the IL-1 antagonist anakinra abrogated expression
of the inflammatory gene signature and attenuated GBM cell proliferation and migration, and increased
apoptosis rates.
The tumor microenvironment, however, is characterized by the presence of a plethora of
inflammatory mediators. Thus, for more lifelike conditions, IL-1β stimulation was substituted
by a newly established model of indirect PBMC/GBM cell co-culture in moderate hypoxia. (Moderate
hypoxia is the prevalent condition within the vital, invasive zone of GBM tumors.) Surprisingly,
sole incubation of GBM cells and PBMCs without any additional stimuli induced inflammatory gene
expression profiles in both GBM cells and PBMCs, highly resembling those found in response to
IL-1β stimulation. Concordantly, increased GBM proliferation rates and enhanced directed tumor
cell migration towards a chemotactic stimulus were found. Apoptosis rates of GBM cells were not
influenced in these indirect co-cultures. In fact, apoptosis was reduced after direct co-culturing of
GBM cells with PBMCs. These findings underscore the role of direct cell–cell contact with T cells as an
inductor of GBM escape mechanisms that prevent them from undergoing apoptosis [39,40].
In the setting of direct or indirect co-culture of immune cells with GBM, anakinra administration
also mitigated proinflammatory gene expression and attenuated the inflammation-induced effects;
GBM cell proliferation and migration were slowed down and apoptosis rate was increased.
GBM-associated inflammation is mounted by a dynamic “crosstalk” between tumor and immune
cells [41–43]. In this regard, activated lymphocytes may be a double-edged sword. On one hand, their
activity as gatekeepers of adaptive immunity is needed [41], but on the other hand, an inflammatory
T-cell phenotype boosts tumor progression. In GBM, the proinflammatory cytokines IL-17 and IL-22
have been identified as cancer-promoting molecules activating oncogenic STAT3 signaling, thereby
protecting GBM cells from apoptosis, promoting GBM proliferation and enhancing invasion [26,27,44].
IL-22 plays a particularly important role in immune cell–tumor interactions, as it is solely secreted
by immune cells and exerts its effects only on non-hematopoietic cells [45]. Additionally, recent
studies have revealed that IFNγ, formerly acknowledged as a prototypical anti-tumor mediator, might
play a multi-functional role in cancer development by displaying tumor-enhancing properties [46,47].
We thus evaluated the influence of anakinra on T cells after co-cultivation with GBM cells, and found
the expression and secretion of IFNγ, IL-17, and IL-22 to be strongly reduced. Moreover, anakinra
treatment shifted T cells towards a more anti-inflammatory phenotype, hampering the secretion of
proinflammatory and enhancing production of anti-inflammatory cytokines without affecting key
molecules of anti-tumor immunity.
Taken together, our data underline the role of IL-1β as a hub of inflammatory signaling within
the tumor microenvironment that drives the tumor-promoting crosstalk between GBM and adaptive
immune cells, and thus promotes GBM aggressiveness. We have provided evidence that this detrimental
feed-forward circuitry can be disrupted and a more benign GBM cell phenotype can be induced in vitro
by administration of anakinra. However, the influence of anakinra on cells of innate immunity, e.g.,
macrophages/macroglia, in the context of GBM remains to be investigated in the future.
The recombinant IL-1 receptor antagonist anakinra is currently approved for the treatment
of rheumatoid arthritis (RA) and several rather rare autoinflammatory diseases, in which it is
self-administered subcutaneously on a daily basis and is generally well tolerated, with skin reactions
at the injection site as the most common treatment-associated side effect [48,49]. Particularly in RA,
studies have demonstrated a decrease of disease-driving inflammatory cytokines IFNγ and IL-17 in
Cancers 2020, 12, 433 8 of 14
patients treated with anakinra. These observed immunomodulating effects have been correlated with
favorable clinical effects such as significant reduction of clinical symptoms and comorbidities like type
2 diabetes [50,51].
As anakinra is able to cross the blood–brain barrier and reaches therapeutically relevant
concentration within the central nervous system [52–54], pharmacological interruption of
tumor-associated inflammation by antagonizing IL-1 signaling might be an interesting new strategy by
which to ameliorate GBM aggressiveness. Our study could provide the experimental basis for future
clinical studies in this direction.
4. Materials and Methods
4.1. Human Tissue Sample
GBM specimens were collected from patients undergoing open tumor resection (Supplementary
Table S2). Brain Tumor Dissociation Kit and gentleMACS dissociator (Miltenyi, Bergisch-Gladbach,
Germany) were used according to the manufacturer’s instructions. Cells were maintained in MACS
Neuro Medium supplemented with 10% FCS, 2% L-Glutamine, 2% penicillin/streptomycin, and 2%
Neuro Brew-21 without vitamin A (Miltenyi, Bergisch-Gladbach, Germany). The study was carried
out following the rules of the Declaration of Helsinki of 1975, revised in 2013, and was approved by the
local ethics committee of the Ludwig-Maximilians University Munich, approval no. 216/14. Written
informed consent was obtained from all patients.
4.2. Cell Culture and Reagents
GBM cell lines U87 and T98G were purchased from the American Type Cell Culture Collection
(ATCC, Manassas, VA, USA), and are routinely authenticated every year by PCR. Cells were cultured
in Dulbecco’s modified Eagle’s medium (DMEM) (Gibco, NY, USA) with 10% fetal calf serum
(FCS) (Biochrom GmbH, Berlin, Germany), 1% non-essential amino acids (Gibco, NY, USA), and 1%
penicillin/streptomycin (Gibco, NY, USA). Cells were incubated at 37 ◦C and 5% CO2, in a humidified cell
culture incubator (Binder, Tuttlingen, Germany), and passaged no more than 10 times. Interleukin-1β
(IL-1β) was purchased from Miltenyi (Cat. No. 130-093-897, Bergisch-Gladbach, Germany) and used
at the concentration of 10ng/mL. Anakinra (Kineret®, Swedish Orphan Biovitrum AB, Stockholm,
Sweden) was used at a final concentration of 1 µg/mL.
4.3. PBMC Isolation
Peripheral blood mononuclear cells (PBMCs) were obtained from healthy donors by venipuncture.
PBMC were isolated from Li-Heparin blood using Histopaque-1077 (Sigma-Aldrich, MO, USA) by
density gradient centrifugation and automatically counted on a Vi-Cell (Beckman-Coulter, Brea, USA).
Viability was >97% in all approaches.
4.4. Co-Cultures
GBM cells were seeded in six well plates (Cellstar®, Greiner Bio-one, Austria) containing 2 mL
DMEM. After adherence, medium was changed to 3 ml RPMI 1640 medium (Gibco), supplemented
with 10% FCS, 1% L-Glutamine, 1% penicillin/streptomycin, and 1% HEPES buffer solution (Gibco),
and PBMCs, stimulated with Human T-Activator CD3/CD28 Dynabeads (Thermo Fisher, Waltham, MA,
USA) were added reaching a final GBM cell–PBMC ratio of 1:10. Cells were incubated in the present or
absence of anakinra (1 µg/mL) under moderate hypoxic conditions in an airtight modular incubator
chamber (Billups-Rothenberg, San Diego, USA) at 5% O2, 40 mmHg CO2 and 37 ◦C. For indirect
co-culture experiments, GBM cells were separated from PBMCs by cell culture inserts (pore diameter:
0.4 µm) (Greiner Bio-one, Austria). After 24 h or 48 h cells, were harvested for further analyses.
Cell culture supernatant was aliquoted and stored at −80 ◦C. Supernatant from direct co-cultures were
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subsequently subjected to native GBM cells, seeded the previous day. After addition of anakinra,
cells were also incubated in moderate hypoxia for 48 h.
4.5. T-Cell Isolation
PBMC from indirect co-culture approaches were harvested after 48 h for T-cell isolation.
Purified T cells were obtained by microbead separation using the Pan T Cell Isolation Kit (Cat. No.
130-096-535, Miltenyi, Bergisch-Gladbach, Germany) and the AutoMACS Pro Separator (Miltenyi,
Bergisch-Gladbach, Germany) according to the manufacturer’s instructions.
4.6. RNA Extraction and cDNA Synthesis
Total RNA was extracted from cell lysates using the RNAqueous Isolation Kit (Ambion, Waltham,
MA, USA) and the TURBO DNA-free Kit (Invitrogen, Waltham, MA, USA) to remove DNA
contamination. RNA sample measurements were conducted using a NanoDrop 2000 spectrophotometer
(Thermo Scientific, Waltham, MA, USA). cDNA was synthesized using Oligo-dT Primers, Random
Hexamers (Qiagen, Venlo, Netherlands), dNTPs, RNAse OUT, and Superscript®III Reverse Transcriptase
(Invitrogen, Waltham, MA, USA) according to the manufacturer’s instructions.
4.7. Quantitative RT- PCR
Quantitative polymerase chain reaction (qPCR) was performed using a LightCycler480
(Roche Diagnostics, Penzberg, Germany) as previously described [55]. TATA Box Binding Protein
(TBP) and Succinate Dehydrogenase Subunit A (SDHA) were used as reference genes. All assays were
designed to be intron spanning. Primers (Metabion, Martinsried, Germany) and UPL Probe numbers
(Roche Diagnostics, Penzberg, Germany) are provided in Supplementary Table S1.
4.8. Flow Cytometry
All cytometric analyses were performed using a BD FACSCanto II flow cytometer (BD, NJ, USA).
Data were analyzed by FlowJo software, version v10 (FlowJo, Ashland, USA). To assess cell proliferation
rate, cells were harvested and stained with Alexa Fluor 488 anti-human Ki-67 antibody (Cat. No.
350507, Clone: Ki-67, BioLegend, CA, USA). Alexa Fluor 488 Mouse IgG1, κ antibody (Cat. No. 400134,
Clone: MOPC-21, BioLegend, CA, USA) was used as isotype control. Staining process for Ki-67 was
conducted following the manufacturer’s protocol. For intracellular staining, cells were permeabilized
and fixated in 70% ethanol (−20 ◦C) for 60 minutes, washed with BioLegend Cell Staining Buffer, and
subsequently incubated with the respective antibody for 30 minutes. Apoptosis assay was conducted
using Violet Chromatin Condensation/Dead Cell Apoptosis Kit (Cat. No. A35135, Invitrogen, Waltham,
MA, USA). A total of 30,000 events were recorded and analyzed respectively.
4.9. Chemotaxis Assay
The chemotaxis assay was conducted using ibidiµ-Slides Chemotaxis (ibidi, Martinsried, Germany)
following the manufacturer’s application guide. Either T98G/primary GBM cells, stimulated with IL-1β
under hypoxic conditions or T98G from indirect co-cultures, incubated in the absence or presence of
anakinra (1 µg/mL), were loaded into slides. After cell adhesion, media in the observation channel was
changed to the respective media without FCS and FCS was applied to one of the adjacent reservoirs,
serving as a chemoattractant. Cell movement in the central channel was observed under constant
incubation at 37 ◦C using an inverted microscope (Zeiss, Jena, Germany; magnification: 10×). Pictures
were taken automatically every 10 minutes for 24 hours. Cell tracking was performed manually using
ImageJ Manual Tracking Plugin (ImageJ, NIH, USA). Data were analyzed using the Chemotaxis and
Migration Tool (ibidi, Martinsried, Germany).
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4.10. Enzyme-Linked Immunosorbent Assay
Supernatants harvested from GBM–PBMC indirect co-cultures were immediately stored at −80 ◦C.
Frozen supernatants were thawed slowly on ice. Measures of 100 µl of supernatant were subjected
to 96 well enzyme-linked immunosorbent assays (ELISA). Cytokine levels were measured using the
respective ELISA MAX™ Deluxe Set according to the manufacturer’s protocols (Interferon γ (IFNγ)
ELISA Kit, Cat. No. 430107, IL-22 ELISA Kit, Cat. No. 434504, IL-17 ELISA Kit, Cat. No.435707, IL-10
ELISA Kit, Cat. No. 430604, BioLegend, San Diego, CA, USA). Optical density was determined using a
FilterMax F3 MultiMode Microplate Reader (Molecular Devices, Munich, Germany) at a wavelength
of 450 nm.
4.11. Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis
Cells were lysed in protein lysis buffer containing protease and phosphatase inhibitors
(Cell Signaling, Danvers, MA, USA). Protein concentrations were measured using a PierceTM BCA
Protein Assay Kit (Thermo Fisher Scientific, Waltham, MA, USA), following the manufacturer’s
instructions. A total 15 µg of protein extract was loaded into each lane of 12% sodium dodecyl
sulfate polyacrylamide gel electrophoresis gels, electrophoresed, and subsequently transferred onto
PVDF membranes. Nonspecific binding was blocked using TBS-Tween-20 (TBST) solution containing
5% non-fat milk. Antibodies for BCL-2 (Clone: D55G8, Cat. No. 4223) and β-Actin (Clone: 13E5,
Cat. No. 4970) were diluted in TBST with 1% non-fat milk. β-Actin was used as loading control.
Immunoreactivity was assessed using horseradish-peroxidase-labeled goat anti-rabbit antibodies
(Cell Signaling, Danvers, MA, USA). Blots were visualized by digital imaging using ClarityTM Western
ECL Substrate kit (Bio-Rad, CA, USA). Densitometric analysis was performed using ImageJ (ImageJ,
NIH, USA).
4.12. Transwell Invasion Assay
Transwell invasion assays were performed using the CytoSelectTM 24-Well Cell Invasion Assay
(Cell Biolabs, Inc. San Diego, CA, USA), following the manufacturer’s instructions. T98G cells,
stimulated with IL-1β, in the absence or presence of anakinra (1 µg/mL), were seeded into rehydrated
cell culture inserts (pore diameter: 8 µm) in serum-free DMEM. DMEM containing 10% FCS was
added to the lower well of the invasion plate. After incubation for 24 h at 37 ◦C, non-invasive cells
were removed from the inside of the inserts with cotton swabs. Invasive cells were stained, lysed, and
the optical densities were determined using a FilterMax F3 MultiMode Microplate Reader (Molecular
Devices, Munich, Germany) at a wavelength of 560 nm.
4.13. Wound Healing Migration Assay
T98G cells stimulated with IL-1β, in the absence or presence of anakinra (1 µg/mL) were seeded in
24 well plates at a density of 200,000 cells/well (Cellstar®, Greiner Bio-one, Austria) and incubated at
37 ◦C with 5% CO2 in FCS-free media. After 24 h, a pipette tip was used to manually scratch a defined
wound through the monolayer of cells. Cell debris was removed by washing the cells once with 1 mL
of media. Washing media was replaced with DMEM containing 10% FCS and cells were incubated for
24 h. Pictures were obtained using an inverted microscope (Carl Zeiss, Jena, Germany).
4.14. Statistics
All data are presented as mean ± SEM unless stated otherwise. Statistical analysis was conducted
using GraphPad Prism 7 software. All datasets were tested for Gaussian distribution, and p-values
were calculated using Student’s t-test or Wilcoxon signed rank test. p < 0.05 was considered statistically
significant (* p < 0.05, ** p < 0.01, *** p < 0.001, n.s. = not significant). All experiments were conducted
at least three times.
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5. Conclusions
In this study, we underscored the role of IL-1β within the GBM signaling network. In human
glioma, IL-1β-related inflammation promotes cancer malignancy and is markedly amplified through
the crosstalk of cancer cells with surrounding immune cells.
By blocking this self-perpetuating circuit, our data highlighted the role of IL-1 receptor antagonist
anakinra as a new potential therapeutic agent in GBM treatment, which merits further investigation.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/12/2/433/s1,
Figure S1: (A) Dose-finding analysis of IL-1β. (B) Dose-finding analysis of anakinra. (C) mRNA expression of
proinflammatory IL-1β, COX2, IL-8 and IL-6 in U87 cells, Figure S2: Analysis of chemotaxis time-lapse microscopy
by single-cell tracking of primary GBM cells, Figure S3: (A) mRNA expression of STAT3 in T98G cells after
stimulation with IL-1β in the present or absence of anakinra, as analyzed by qRT-PCR. (B) Percentage of apoptotic
T98G cells after stimulation with IL-1β, in the present or absence of anakinra, as measured by flow cytometry,
Table S1: Primer sequences for qRT-PCR, Table S2: Patient characteristics.
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